Ms. Haddad has extensive experience in representing buyers, sellers and financial advisors in merger and acquisition transactions involving both public and private companies, especially in the life sciences and technology sectors. In this area, she has a special focus on public company mergers and acquisitions and other complex transactions involving public companies. Ms. Haddad also advises public companies on a wide variety of corporate and securities matters and represents public companies as general corporate and securities law counsel. In that capacity, she provides advice in all aspects of corporate governance and securities law compliance.
Her recent experience includes representing:
- MyoKardia in its $13.1 billion sale to Bristol Myers Squibb
- Spark Therapeutics in $4.4 billion sale to Roche
- Centerbridge Partners in its $1.4 billion acquisition of Civitas Solutions
- Ipsen in its $1.3 billion (upfront cash and CVR) acquisition of Clementia Pharmaceuticals
- Foundation Medicine in its $1.0 billion sale of a majority stake to Roche and subsequent $2.4 billion negotiated tender offer for the public minority interest by Roche
- PTC in connection with a strategic partnership and $1.0 billion investment by Rockwell Automation
- First Eagle Investment Management in its $500 million (upfront cash and CVR) acquisition of NewStar Financial
- Neustar in its $2.9 billion sale to Golden Gate Capital
- Cornerstone OnDemand in connection with a $300 million strategic investment led by Silver Lake
- Citrix Systems in a $2.9 billion Reverse Morris Trust transaction involving the merger of a division of Citrix with LogMeIn
- LoJack Corporation in its $135 million sale to CalAmp Corp.
- Teva Pharmaceutical in its $3.2 billion acquisition of Auspex Pharmaceuticals
- Trulia in its $3.5 billion sale to Zillow
- Eloqua in its $1.0 billion sale to Oracle
- Citrix Systems in its cooperation agreement with Elliott Management
- Cognex Corporation in the sale of its surface inspection systems division to AMETEK
- Teva Pharmaceutical in the sale of its animal health division to Bayer
- Haemonetics Corporation in its acquisition of Pall Corporation's blood collection, filtration and processing product lines
